Aug 12, 2020
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
Jun 12, 2020
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 04, 2020
OncoSec to Present at Virtual Summer Investor Summit
May 31, 2020
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
May 29, 2020
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
May 27, 2020
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
May 21, 2020
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7(TM) in Glioblastoma Multiforme
May 14, 2020
Leap Therapeutics Reports First Quarter 2020 Financial Results
May 13, 2020
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
May 13, 2020
OncoSec's TAVO(TM) Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma
May 12, 2020
Non-Small Cell Lung Cancer (NSCLC) Market Forecasts to 2030: A Comprehensive Insight
May 08, 2020
FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion
May 07, 2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
May 06, 2020
FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer
May 06, 2020
OncoSec's TAVO(TM) in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'
May 06, 2020
Compugen Reports First Quarter 2020 Results
Apr 22, 2020
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
Apr 22, 2020
FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments